We use technology to improve diagnostic and treatment accuracy for patients. We develop state of the art solutions to improve clinical outcome, and hence improve quality of life.
Biobot Surgical Pte Ltd aims to be a global technology leader in minimally-invasive robotic healthcare solutions.
Biobot Surgical Pte Ltd was incorporated in 2007 in Singapore, and became a member of ZIG Venture since 2011.
To ensure success, a team of talents has been put together in the areas of robotic design and technology, medical image processing, software development and clinical application.
To date, the iSR’obot Mona Lisa has obtained key regulatory approvals, including Europe (CE mark), U.S.A (US FDA), Australia (TGA) and Singapore (HSA) and is being used in some of the most prestigious hospitals around the world.
Striving to become the gold standard in diagnosis and prognosis of prostate cancer, the Mona Lisa’s development has been a process of evolution and is the latest in our state of the art new generation designs.
We are proud to share our debut showcase in Myanmar at the 4th Myanmar Nephro-Urology Society Conference held over the weekend on 12-13 Oct 2019.
We are honoured to be exhibiting again this year at the Asia Pacific MedTech Forum 2019 at Booth No. 3. This year’s theme is “Connecting Leaders, Connecting Care”.
Thank you everyone who visited our booth!
“Robotic prostate biopsy and needle localization are technological developments that have the potential to positively influence the diagnosis and management of prostate cancer. All of that enables more precise and accurate localization of targets”
Dr. dr. Irfan Wahyudi, Sp.U (K), Head of the Urology Department of RSCM-FKUI, in Jakarta
(Article in bahasa Indonesia; quote based on google translation )
Thank you for visiting us at Asia-Pacific Prostate Cancer Conference 2019!
“For example, Singapore General Hospital worked with Biobot Surgical to develop a robotic system that conducts prostate biopsies using a navigation platform to position a needle that can target tumour areas accurately.
The system – used in Singapore hospitals and in Australia and Europe – has performed prostate biopsies on more than 6,000 patients. Biobot Surgical’s chief executive Sim Kok Hwee is hoping to break into the China market next year with an upgraded robotic system that contains both diagnostic and treatment functions, including cryotherapy, which freezes and kills prostate cancer cells.”